Search results
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 7 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
AstraZeneca withdraws COVID-19 vaccine citing low demand
KSBW Salinas· 12 hours agoAstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a...
Earnings call: Moderna reports a net loss of $12.2 billion By Investing.com
Investing.com· 6 days agoThe biotechnology company, known for its mRNA vaccine technology, highlighted its strategic...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 7 days agoMuch of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a...
AstraZeneca to withdraw COVID-19 vaccine worldwide due to low demand
WXYZ-TV Detroit· 9 hours agoDrugmaker AstraZeneca is reportedly pulling its COVID-19 vaccine from global markets due to a...
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Investor's Business Daily· 6 days agoBut it can be serious or deadly in babies and older adults. The FDA is due to make its decision on ...
AstraZeneca Is Withdrawing Its Covid Vaccine Worldwide, Citing Low Demand
New York Times· 10 hours agoThe shot is no longer being manufactured or supplied, and it is no longer authorized for use in...
Moderna (NASDAQ:MRNA) Stock Price Down 3.4% Following Insider Selling
ETF DAILY NEWS· 1 day agoShares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) dropped 3.4% during trading on Monday after an insider sold shares in the company. The company traded as low as $120.38 ...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
NBC Philadelphia· 7 days agoModerna posted a narrower-than-expected loss for the first quarter as the company's cost-cutting...
Moderna Focused on Cutting Costs, RSV Vaccine
Bloomberg· 7 days agoModerna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker expects to...